ALK heading to FDA with dust mite vaccine
ALK and Big Pharma partner Merck have wrapped up a phase III trial with the Danish company’s vaccine against dust mite allergy. The partners are now discussing plans for an application with the FDA.
BY STEFAN SINGH KAILAY & LONNI LYNGE
ALK’s oral vaccine to treat house dust mite allergy has excelled in a new phase III study conducted by its Big Pharma partner Merck, known as MSD outside of North America, the Danish-based company says in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ALK CEO looks to the allergy products of the future
For abonnenter
Merck: We want to expand the partnership with ALK
For abonnenter
ALK to close Swiss business unit
For abonnenter
